Undifferentiated prostate cancer treated with docetaxel

Abstract

Introduction Undifferentiated prostate cancer is a rare and aggressive disease, and no definitive therapeutic strategy for metastatic undifferentiated prostate cancer has been established. Case presentation We report the case of a 70‐year‐old man with undifferentiated prostate cancer and lymph node metastases. Following the patient’s progression after platinum‐based chemotherapy, we initiated treatment with docetaxel, which resulted in a partial response. The patient was alive for 42 months after initiation of docetaxel, maintaining relatively good quality of life with minimal hospital stay. Conclusion Docetaxel may be a good therapeutic option for metastatic undifferentiated prostate cancer.

Keywords

• chemotherapy
• docetaxel
• prostate cancer
• quality of life
• undifferentiated carcinoma